In a report released yesterday, Kallum Titchmarsh from Morgan Stanley maintained a Buy rating on IQVIA Holdings, with a price target of $240.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Kallum Titchmarsh has given his Buy rating due to a combination of factors, including a solid first quarter and a resilient demand backdrop across IQVIA’s core businesses. He notes that, despite broader CRO sector worries, IQVIA continues to show mid‑single‑digit organic growth and high‑single‑digit EPS expansion, supported by constructive trends in both large pharma and emerging biotech customers.
He also highlights that forward-looking indicators such as the qualified pipeline and RFP flow are growing at healthy rates, suggesting bookings remain fundamentally sound even after adjusting for pass‑through mix effects. In his view, the stock’s valuation at roughly 11x next‑twelve‑month earnings does not fully reflect this steady growth profile or the stable competitive positioning versus peers, supporting an unchanged $240 price target and a continued Buy stance.
In another report released today, Barclays also maintained a Buy rating on the stock with a $210.00 price target.